Article Information
History
- November 29, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- David Eyre*,1,2,3,**,
- Matthias Futschik*,4,
- Sarah Tunkel4,
- Jia Wei5,
- Joanna Cole-Hamilton4,
- Rida Saquib4,
- Nick Germanacos4,
- Andrew R Dodgson6,
- Paul E Klapper7,
- Malur Sudhanva8,
- Chris Kenny4,
- Peter Marks4,
- Edward Blandford4,
- Susan Hopkins9,
- Tim Peto2,3,5 and
- Tom Fowler4
- 1Big Data Institute, Nuffield Department of Population Health, University of Oxford, UK
- 2NIHR Oxford Biomedical Research Centre, University of Oxford, UK
- 3NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, UK
- 4Public Health and Clinical Oversight (PHCO), UK Health Security Agency, London, UK
- 5Nuffield Department of Medicine, University of Oxford, UK
- 6UK Health Security Agency, Department of Microbiology, Manchester Public Health Laboratory, Manchester, UK
- 7Division of Evolution, Infections and Genomics, University of Manchester, UK
- 8South London Specialist Virology Centre, Infection Sciences, King’s College NHS Foundation Trust, London, UK
- 9UK Health Security Agency, London, UK
- ↵** Corresponding author; email: david.eyre{at}bdi.ox.ac.uk
↵* equal contributors
Posted November 29, 2022.
Performance of antigen lateral flow devices in the United Kingdom during the Alpha, Delta, and Omicron waves of the SARS-CoV-2 pandemic
